January 7, 2026
Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.
Today’s edition runs from federal doctrine to shelf-level risk: the Supreme Court tees up Hemani, a marijuana and gun rights case that turns on how “current use” gets defined, while the November 2026 hemp rewrite is already hardening lender and retailer posture. We also cover Ohio’s late THC beverage veto, Florida’s tightening medical economics, and the state-by-state grind that keeps rewriting what “normal” looks like for patients and consumers.
Policy, Decoded is produced by THC Group. We advise operators, brands, trade groups, investors, and policymakers on cannabis and hemp regulation, legislative strategy, compliance posture, and crisis-response when the rules or market need updating. If you need help reading the rumor mill, pressure-testing a plan, or getting ahead of the next enforcement trend, reach out. We’re here to help.
Also listen to The Hybrid podcast hosted by former regulators Shawn Collins and Erik Gundersen. New episodes are coming in the New Year!
⚖️ Hemani cannabis gun rights case
🌾 2026 hemp THC definition cliff
🥤 Ohio THC beverage veto surprise
Write it down. Then do it that way.
The deeper pattern behind today’s moves — and why it matters next.
Cannabis And Gun Ownership Head To The Supreme Court
🧾 Context: The Supreme Court will hear arguments on March 2, 2026 in United States v. Hemani, a challenge to the federal gun ban for anyone deemed an “unlawful user” of a controlled substance under 18 U.S.C. § 922(g)(3). The law hits cannabis in a uniquely modern way, since millions of adults live in legal states where use feels ordinary, while federal firearms rules still treat marijuana as disqualifying. The flashpoint sits inside the federal purchase form and the government’s definition of “current use,” which can reach well beyond same-day impairment. Post Bruen and Rahimi, courts have started pulling in different directions on whether Congress can disarm by status alone or needs a tighter tie to danger. That split is now on the Court’s desk, with an opinion likely by late June or early July.
🔎 What It Signals: This case is about how the federal government proves risk. A broad government win keeps a simple enforcement tool: prosecutors can treat the “user” label as enough, and the fight stays mostly about whether the person fits the label. A narrowing decision changes the center of gravity toward proof that ordinary people recognize as fair, including recency, impairment, and a clearer timeline for what counts as “current.” That kind of ruling also invites a fast second wave over the ATF definition itself, because an inference-based standard becomes harder to defend when the Court starts demanding a closer fit between use and firearm danger. Either way, the opinion will set the tone for how aggressively federal actors treat state-legal cannabis as a rights-disabling fact, even while Washington is publicly flirting with reform.
🧠 THC Group Take: This is one of those federal rules that turns decent people into quiet rule-breakers. Plenty of adults can buy regulated cannabis on Saturday, go home, lock a lawfully owned firearm in a safe, and still carry federal exposure that feels untethered to how they actually live. They are not waving a gun around. They are not high at a range. They are not looking for trouble. They are doing the ordinary things that state law has told them, for years, are ordinary.
That mismatch is why this case matters. The Court is not deciding whether cannabis is good or bad. It is deciding how much the federal government can assume about dangerousness based on a label that often rests on timing and inference rather than impairment. A tightening decision pulls prosecutors toward proof that passes a gut check. A broad government win preserves a rule that treats state compliance as irrelevant when a constitutional right is on the other side of the scale.
After the ruling, the first practical question will be plain: how current is current, and who has to prove it. Until then, the only honest posture is to acknowledge uncertainty. Confident folk wisdom in this space turns into evidence fast, and it tends to land hardest on people who were trying to do the right thing.
Fast-moving headlines, flagged for what matters.
Hemp processors and brands are warning that a pending federal definition change could wipe out most hemp derived THC commerce by imposing a tight total THC cap. The exposure runs straight through extraction economics, since concentrates feed tinctures, edibles, and beverages that have carried a lot of acreage. Advocates are pitching Congress a replacement framework centered on labeling integrity, synthetic THC restrictions, and youth protections. The policy risk lands early because lenders, buyers, and insurers harden terms long before an effective date. If Congress does not create a workable lane, purchase commitments shrink and hemp snaps back into a boom bust crop. (WXPR; Farms.com)
C-store trade press is already warning retailers that the federal hemp rewrite set for November could force a rapid retreat from products many stores treated as reliable margin. The analysis leans on industry arguments that the revised definition would pull most items into unlawful territory and leave remaining formats hard to manufacture at scale. It also highlights the mixed federal posture, with the White House pushing rescheduling while urging Congress to preserve access to appropriate full spectrum CBD. Retailers do not wait for clarity when liability sits on the shelf. If this framing spreads, mainstream pullback becomes the market signal that hits suppliers first. (C-Store Dive)
Ohio’s intoxicating hemp crackdown forced a reset, then DeWine escalated it with a line item veto that erased the THC beverage runway after two years of public focus on gummies and kid facing retail. Beverage makers built around age gated distribution and familiar beer and wine logistics, then watched the category get swept into the same short fuse timeline with little public warning. The episode reinforces a hard operating truth in this space: compliance posture does not insulate a category from late stage political edits when leadership wants a clean headline. It also gives Congress a cautionary exhibit as lawmakers debate federal hemp rewrites, because uncertainty gets priced as aggressively as prohibition. The consequence is chilled investment in any model that depends on stable channel rules, including models built to look responsible. (Cleveland.com)
The Senate confirmed Sara Carter as Director of the Office of National Drug Control Policy yesterday in a 52 to 48 vote. ONDCP shapes White House drug policy priorities and tone, which matters while DOJ works through the Schedule III rulemaking path. Carter has expressed support for medical cannabis, which fits a patient and research frame the administration can use. The job still carries statutory constraints and a mandate to show drug control outcomes, so the posture will show up in strategy language and interagency coordination. Watch how quickly ONDCP draws a bright line between regulated markets and illicit supply in public messaging. (Politico)
The U.S. Supreme Court will hear arguments on March 2nd in a case testing the federal ban on gun possession by unlawful users of controlled substances, a category that still includes marijuana. The dispute turns on everyday conduct that state programs have normalized, while federal forms and federal possession law treat use as disqualifying. The justices will weigh that rule against the Court’s modern Second Amendment framework, which has already reshaped prohibited person litigation. A decision by early summer could narrow enforcement, push Congress toward a clearer statutory line, or cement the status quo with new precedent. The outcome will define how much legal risk attaches to lawful state cannabis use for millions of adults. (Cannabis Wire)
Assembly Speaker Robin Vos says Wisconsin lacks the votes for medical cannabis and calls the Schedule III push the wrong move. He leans on public safety arguments and points to harms he says other states have experienced. He also concedes Schedule III could loosen research barriers, which is the one path that could change the medical debate over time. Senate Republicans continue to float a medical bill, while the Assembly remains the chokepoint. With a governor’s race ahead and public support rising, leadership is signaling the bottleneck stays political, not technical. (Marijuana Moment)
Florida’s OMMU data shows 930,226 active patients, with annual patient growth down to 3.9% as of the week ending January 1st. Store count keeps climbing, reaching 738 dispensaries, which spreads volume thinner and intensifies discounting. New Cannabis Ventures points to a widening gap between unit movement and revenue, which tracks price compression and promotion dependence. The adult use ballot loss removed the near term growth story that supported expansion plans. 2026 becomes an execution year where operators win on productivity, retention, and cost control. (New Cannabis Ventures)
A coalition has launched Respect Nebraska Voters, a constitutional amendment campaign designed to make it harder for lawmakers to rewrite or overturn laws passed by voters. The proposal would require a four fifths vote of the Legislature to amend or repeal voter approved measures and apply the same threshold to changes in the initiative process itself. Organizers tie the effort to multiple ballot fights, including the stalled implementation of voter approved medical marijuana. To qualify for the November 2026 ballot, they must gather signatures from about 10% of registered voters with county distribution requirements by early July. If it advances, it becomes a direct test of whether Nebraska treats voter initiatives as durable lawmaking or provisional outcomes. (Nebraska Public Media)
A newly filed Virginia bill would require hospitals and similar facilities to allow terminally ill patients to use medical cannabis with a valid written certification. The bill bans smoking and vaping and pushes facilities to build protocols for storage, documentation in the medical record, and staff guidance. It carves out emergency departments and emergency medical services during active emergency care. A federal safety valve lets a facility pause compliance if DOJ, CMS, or another federal regulator initiates an enforcement action tied to the policy or issues an express prohibition. If this moves, access turns into bedside procedure and institutional risk management fast. (Marijuana Moment)
Cannabis Cultivators of British Columbia wants the province to formally recognize cannabis as a priority economic sector and open access to existing economic development programs. Their 2026 policy paper ties the request to competitiveness, investment, and export readiness, including a provincial origin designation aimed at protecting reputation and consumer confidence. The group also calls for lower friction inside the legal channel, including a single national excise stamp and wider eligibility for direct delivery. They want excise remittance mechanics that track wholesale realities rather than punishing compliant distribution. If the province engages, it marks a shift toward an export capable posture instead of managed decline. (MMJDaily)
UK police forces are being issued national guidance on how to handle people carrying prescribed cannabis based medicines. The document tells officers to assume lawful patient status unless facts support a different conclusion and start with practical checks such as original packaging, dispensing label, and matching ID. It notes patients may have a prescriber letter or prescription copy, while carrying those documents is not required. The guidance pushes verification through a clinic or prescriber when needed and narrows seizure first instincts. If implemented seriously, patients see fewer disruptive stops and police free up time for higher value work. (The Telegraph)
Jersey in the Channel Islands will ban advertising of prescription only medicines, including medicinal cannabis, when its Medicines Advertising Order takes effect January 13th. Health officials tied the change to unsafe prescribing concerns and mental health harms, with medicinal cannabis promotion cited as part of the problem. The rules target direct advertising and indirect lifestyle marketing, plus endorsements and exaggerated claims. Breaches become criminal offenses with potential fines and jail time. Clinics that relied on marketing now face a tighter lane that pushes demand toward clinical decision making and documented need. (Bailiwick Express)
A new Cureus review synthesizes the literature on cannabis use in orthopaedic surgery and finds no consistent opioid sparing benefit tied to routine perioperative use. Preclinical work points in different directions depending on cannabinoid profile, with cannabidiol showing some bone related promise and higher THC exposure raising inhibition concerns. Clinical studies still struggle to control for product type, dose, and use pattern, which limits clean conclusions. Some fracture data shows no clear signal on union complications, while arthroplasty focused analyses link cannabis history to higher complication risk across endpoints. Expect hospitals and surgeons to formalize screening and perioperative guidance because protocol follows risk. (Cureus)
DePaul University is offering a dispensary management course focused on the mechanics that dominate compliance work, including training, recordkeeping, and storage. The timing is awkward because the rule set still evolves faster than most syllabi and the best learning remains inside real stores under margin pressure. The useful value is transferable discipline, including documentation habits and customer safety thinking. The risk is students paying for a credential that cannot keep pace with enforcement discretion and market churn. The sector will judge competence at the vault and the register, not on a transcript. (Fox News)
Indiana Rep. Mitch Gore filed a bill to remove penalties for possessing or growing up to two ounces of marijuana, without creating a licensed sales market. The proposal keeps hashish and hash oil prohibited, drawing a bright line around concentrates. It also raises the felony threshold for possession from 30 grams to four ounces, changing charging leverage and plea dynamics. The bill heads to the House Courts and Criminal Code Committee, where similar efforts have struggled. Even without a clear path, it frames reform around proportionality and enforcement rather than commercial rollout. (Marijuana Moment)
From the hearing room to the comment section — we’re watching it all.
🍸 Seed money is still finding its way into hemp THC drinks when the brand pitch is tight and the compliance posture looks disciplined. Jeng’s raise also shows how investors are betting on low dose social formats that borrow RTD cues and speak to specific consumers rather than chasing everyone at once. (BevNET)
🤖 Utah is piloting a program that lets an AI system renew certain routine prescriptions for chronic conditions with no physician involvement in the default workflow, with limits on drug classes and human review baked in at the front end. It is an early example of a state building a legal lane for automated clinical decisions, and it will pressure medical boards and lawmakers to define where the line sits for safety, liability, and controlled substances. (Politico)
💉 GLP 1 drugs like Ozempic reshape appetite and reward signaling, and early data hints they may reduce problematic cannabis use without changing why people use cannabis day to day. The practical issue is mechanics, because slowed digestion and overlapping nausea can change how edibles feel and how much appetite comes back when THC enters the mix, so disclosure to a clinician becomes a safety habit rather than a confession. (GreenState)